**UNITED STATES**
**SECURITIES AND EXCHANGE COMMISSION**
**Washington, D.C. 20549**

# FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of July 2016

_____

Commission File Number: 001-36826

# ADVANCED ACCELERATOR APPLICATIONS S.A.

**(Exact name of registrant as specified in its charter)**

**20 rue Diesel**
**01630 Saint Genis Pouilly, France**
**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F X Form 40-F _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No X

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No X

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**ADVANCED ACCELERATOR APPLICATIONS S.A.**

By: /s/ Heinz Mäusli
Name: Heinz Mäusli
Title: Chief Financial Officer

Date: July 27, 2016

**ADVANCED ACCELERATOR APPLICATIONS S.A.**

**EXHIBIT INDEX**

| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release titled "Advanced Accelerator Applications Announces Opening of First U.S. Manufacturing Facility; Preparation for Anticipated Lutathera Launch" |
| 99.2 | Press Release titled "Advanced Accelerator Applications Announces FDA Priority Review for Lutathera" |
| 99.3 | Press Release titled "Advanced Accelerator Applications Expands U.S. NETSPOT™ Supply Chain with Two Additional Radiopharmacy Networks" |
| 99.4 | Press Release titled "Cardinal Health to Prepare NETSPOT™ Doses for Advanced Accelerator Applications" |
| 99.5 | Press Release titled "Advanced Accelerator Applications Announces Expansion of Theranostic Pipeline with NeoBOMB1" |
| 99.6 | Press Release titled "Advanced Accelerator Applications Expands its Presence in Germany with Strategic Acquisition of Two Production Sites" |
| 99.7 | Press Release titled "Advanced Accelerator Applications Appoints Francois Nader, M.D., to Board of Directors" |
| 99.8 | Press Release titled "Advanced Accelerator Applications Preparing for Lutathera Launch by Scaling Up Production in Ivrea, Italy" |
| 99.9 | Press Release titled "ITEL Signs Agreement with Advanced Accelerator Applications to Commercialize F-18 Radiopharmaceuticals in Southern Italy" |

**Exhibit 99.1**

# PRESS RELEASE

## Advanced Accelerator Applications Announces Opening of First U.S. Manufacturing Facility; Preparation for Anticipated Lutathera Launch

**Saint-Genis-Pouilly, France - July 26, 2016 – Advanced Accelerator Applications S.A. (NASDAQ:AAAP)** ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), today announced the opening of its first U.S. manufacturing facility in Millburn, NJ.

The 15,000 square foot facility features 12 production lines dedicated to Lutathera, as well as storage and office space. The site is conveniently located near Newark airport, enabling future delivery of Lutathera directly to hospitals and treatment centers around the country. There are currently more than 15 pharmaceutical manufacturing, sales and marketing, and administrative employees working on site, with plans to expand to 50 people.

In addition, the Millburn plant serves as a distribution center for NETSPOT™, a AAA product recently approved by the U.S. Food and Drug Administration for the preparation of Gallium Ga 68 dotatate for injection, a first in class drug for the localization of somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients using Positron Emission Tomography ("PET"). Oxygen-18 enriched water, an important precursor for the production of fluorodeoxyglucose used in PET, is also distributed by the new facility on behalf of Marshall Isotopes, a AAA company.

*"We are excited to have our first U.S. manufacturing facility operational in preparation for the anticipated approval and launch of Lutathera,"* said Stefano Buono, Chief Executive Officer of AAA. *"The Millburn plant is our 22nd manufacturing site globally and we believe this facility will provide us with sufficient capacity to meet future demand for Lutathera in the North American market and manage distribution of our new generation of PET products*."

---

**About Lutathera**

Lutathera (or lutetium Lu 177 dotatate) is a Lu-177-labeled somatostatin analogue peptide currently in development for the treatment of gastro entero pancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy ("PRRT"), which involves targeting carcinoid tumors with radiolabeled somatostatin analogue peptides. This novel compound has received orphan drug

designation from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Lutathera was also granted fast-track designation by the FDA in April 2015 for the treatment of inoperable progressive midgut NETs. Lutathera is also currently administered on a compassionate use and named patient basis for the treatment of NETs and other tumors over-expressing somatostatin receptors in ten European countries and in the US under an Expanded Access Program (EAP) for midgut NETs. In an analysis of the Phase 3 trial's primary endpoint of PFS assessment completed by the Company in September 2015, the number of disease progressions or deaths was 23 events in the Lutathera arm and 68 in the Octreotide LAR 60 mg arm. The NETTER-1 study met its primary endpoint by demonstrating that treatment with Lutathera was associated with a statistically significant and clinically meaningful risk reduction of 79% of disease progression or death versus Octreotide LAR 60 mg (hazard ratio 0.21, 95% CI: 0.13-0.33; p<0.0001).

NDA and MAA submissions to the FDA and EMA are currently under review and the FDA has granted Priority Review.

**About Advanced Accelerator Applications**

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA's lead therapeutic product candidate, Lutathera, is a novel MNM compound that AAA is currently developing for the treatment of Neuro Endocrine Tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 22 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 450 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). AAA reported sales of €88.6 million in 2015 (+26.8% vs. 2014) and sales of €26.9 million for 1Q 2016 (+29.6% vs. 1Q15). AAA is listed on the Nasdaq Global Select Market under the ticker "AAAP". For more information, please visit: www.adacap.com.

**Cautionary Statement Regarding Forward-Looking Statements**

This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our

product candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates; our ability to procure adequate quantities of necessary supplies and raw materials for Lutathera and other chemical compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely and safe delivery of our products or product candidates by third parties; any problems with the manufacture, quality or performance of our products or product candidates; the rate and degree of market acceptance and the clinical utility of Lutathera and our other products or product candidates; our estimates regarding the market opportunity for Lutathera, our other product candidates and our existing products; our anticipation that we will generate higher sales as we diversify our products; our ability to implement our growth strategy including expansion in the U.S.; our ability to sustain and create additional sales, marketing and distribution capabilities; our intellectual property and licensing position; legislation or regulation in countries where we sell our products that affect product pricing, taxation, reimbursement, access or distribution channels; and general economic, political, demographic and business conditions in Europe, the U.S. and elsewhere. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

**Contacts:**

**AAA Corporate Communications**
Rachel Levine
Director of Communications
rachel.levine@adacap.com
Tel: + 1-212-235-2395

**AAA Investor Relations**
Jordan Silverstein
Director of Investor Relations
jordan.silverstein@adacap.com
Tel: + 1-212-235-2394

**Media inquiries**

**FTI Consulting**
Shauna Elkin
shauna.elkin@fticonsulting.com
Tel: +1-212-850-5613

**Axess Public Relations (Italy)**
Dario Francolino
dario.francolino@axesspr.com
Tel: +39 3488818029

**Exhibit 99.2**

## PRESS RELEASE

# Advanced Accelerator Applications Announces FDA Priority Review for Lutathera

**Saint-Genis-Pouilly, France - June 27, 2016 – Advanced Accelerator Applications S.A. (NASDAQ:AAAP)** ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) and granted Priority Review for Lutathera, a Lu-177-labeled somatostatin analogue peptide currently under development for the treatment of gastro entero pancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. The Prescription Drug User Fee Act (PDUFA) target action date is December 28, 2016.

Priority review is assigned to applications for drugs that treat serious conditions and would, if approved, provide significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions.

The Lutathera NDA is based on the results of a randomized pivotal Phase 3 study, NETTER-1 that compared treatment using Lutathera with a double dose of Octreotide LAR in patients with inoperable midgut NETs progressive under Octreotide LAR treatment and overexpressing somatostatin receptors. The NETTER-1 study met its primary endpoint by demonstrating that treatment with Lutathera was associated with a statistically significant and clinically meaningful risk reduction of 79% in disease progression or death versus a treatment with a double dose of Octreotide LAR. Efficacy and safety data from a large Phase I-II trial conducted in more than 1,200 patients in NET indications is also part of the NDA.

*"We are encouraged that the FDA has granted Priority Review for Lutathera as a potential treatment for GEP-NETs," said Stefano Buono, Chief Executive Officer of AAA. "We believe this action emphasizes the need to improve the lives of these patients."*

---

**About Neuro Endocrine Tumors (NETs)**

Neuro Endocrine Tumors, also known as NETs, are a group of tumors originating in the neuroendocrine cells of many different organs. NETs can remain clinically silent for years delaying the diagnosis in a large number of patients. These cancers are rare but they are the second most common type of gastrointestinal malignancy and their incidence is increasing. The estimated incidence of NETs for the combined populations of the United States and the European Union is approximately 47,300.

NETs are classified as orphan diseases by U.S. and European regulatory authorities, meaning that they affect a relatively small population of individuals in the relevant jurisdiction. In the United States, orphan drugs are defined as drugs that treat diseases or conditions that affect 200,000 or fewer individuals in the country. In the European Union, orphan drugs are defined as drugs that treat diseases or conditions that affect fewer than five out of 10,000 individuals in the European Union.

**About Lutathera**

Lutathera (or lutetium Lu 177 dotatate) is a Lu-177-labeled somatostatin analogue peptide currently in development for the treatment of gastro entero pancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy ("PRRT"), which involves targeting carcinoid tumors with radiolabeled somatostatin analogue peptides. This novel compound has received orphan drug designation from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Lutathera was also granted fast-track designation by the FDA in April 2015 for the treatment of inoperable progressive midgut NETs. Lutathera is also currently administered on a compassionate use and named patient basis for the treatment of NETs and other tumors over-expressing somatostatin receptors in ten European countries and in the US under an Expanded Access Program (EAP) for midgut NETs. In an analysis of the Phase 3 trial's primary endpoint of PFS assessment, completed by the Company in September 2015, the Lutathera arm of the trial demonstrated a significant improvement in PFS compared to the PFS for Octreotide LAR 60 mg arm, suggesting a significant therapeutic effect for patients with midgut NETs. NDA and MAA submissions to the FDA and EMA are currently under review.

**About Advanced Accelerator Applications**

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA's lead therapeutic product candidate, Lutathera, is a novel MNM compound that AAA is currently developing for the treatment of Neuro Endocrine Tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 20 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 440 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). AAA reported sales of €88.6 million in 2015 (+26.8% vs. 2014) and sales of €26.9 million for 1Q 2016 (+29.6% vs. 1Q15). AAA is listed on the Nasdaq Global Select Market under the ticker "AAAP". For more information please visit: www.adacap.com.


**Cautionary Statement Regarding Forward-Looking Statements**

This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our product candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates; our ability to procure adequate quantities of necessary supplies and raw materials for Lutathera and other chemical compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely and safe delivery of our products or product candidates by third parties; any problems with the manufacture, quality or performance of our products or product candidates; the rate and degree of market acceptance and the clinical utility of Lutathera and our other products or product candidates; our estimates regarding the market opportunity for Lutathera, our other product candidates and our existing products; our anticipation that we will generate higher sales as we diversify our products; our ability to implement our growth strategy including expansion in the U.S.; our ability to sustain and create additional sales, marketing and distribution capabilities; our intellectual property and licensing position; legislation or regulation in countries where we sell our products that affect product pricing, taxation, reimbursement, access or distribution channels; and general economic, political, demographic and business conditions in Europe, the U.S. and elsewhere. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

**Contacts:**

**AAA Corporate Communications**
Rachel Levine
Director of Communications
rachel.levine@adacap.com
Tel: + 1-212-235-2395

**AAA Investor Relations**
Jordan Silverstein
Director of Investor Relations
jordan.silverstein@adacap.com
Tel: + 1-212-235-2394

**Media inquiries**

**FTI Consulting**
Shauna Elkin
shauna.elkin@fticonsulting.com
Tel: +1-212-850-5613

**Axess Public Relations (Italy)**
Dario Francolino
dario.francolino@axesspr.com
Tel: +39 3488818029

**Exhibit 99.3**

# PRESS RELEASE

## Advanced Accelerator Applications Expands U.S. NETSPOT™ Supply Chain with Two Additional Radiopharmacy Networks

**Saint-Genis-Pouilly, France - June 10, 2016 – Advanced Accelerator Applications S.A. (NASDAQ:AAAP)** ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), today announced that it has further strengthened its U.S. supply chain for NETSPOT™ with the addition of two radiopharmacy networks, Triad Isotopes, Inc., the second largest radiopharmaceutical company in the United States, and Nuclear Diagnostic Products, Inc. ("NDP"), a company with three radiopharmacies in the Northeast and a member of United Pharmacy Partners Inc. ("UPPI"), to supply gallium 68 ("Ga 68") dotatate doses prepared with a novel kit to U.S. hospitals and imaging centers.

NETSPOT™ (formerly known as Somakit-TATE) is a patented kit recently approved by the U.S. Food and Drug Administration ("FDA") for the preparation of Ga 68 dotatate for injection, for the localization of somatostatin receptor positive neuroendocrine tumors ("NETs") in adult and pediatric patients using Positron Emission Tomography ("PET"). The product has received orphan drug designation from the FDA.

Triad and NDP will each prepare and deliver NETSPOT™ patient doses to advanced medical imaging sites in selected metropolitan areas. The addition of these partnerships completes the foundation of a robust nationwide supply chain that now includes four radiopharmacy networks.

*Marc Pfefferle, Chief Executive Officer of Triad stated, "We are excited about this opportunity and the ability to provide the benefits of NETSPOT™ to our customers. With our large pharmacy network, we continue to provide world renowned technical expertise in the compounding and delivery of radiopharmaceuticals."*

*Wayne Wong, Vice President of Product Development for NDP noted, "Nuclear Diagnostic Products, Inc. is committed and looking forward to serving patients and nuclear medicine departments with the preparation and delivery of NETSPOT™. NDP's experience and expertise in customer service will support NETSPOT™ distribution, one patient at a time."*

*Stefano Buono, Chief Executive Officer of AAA said, "With the addition of these new supply chain relationships, we are well positioned to initiate the launch of NETSPOT™. We believe that Triad and NDP both bring significant capabilities to our network, including Triad's broad footprint and extensive experience with neuroendocrine tumor products, and NDP's strong position and customer focus in the Northeast region of the country. We look forward to working closely with all of our partners and expanding the potential market reach of NETSPOT™. We believe in the potential of NETSPOT™ to improve the accuracy of diagnoses of NETs and our goal is to provide access for as many patients as possible."*


---

**About NETSPOT™**

NETSPOT™ is a novel patented kit developed by AAA for the preparation of gallium Ga 68 dotatate for injection, for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients using Positron Emission Tomography ("PET"). The kit has been designated as an orphan drug by the EMA and the FDA. For full prescribing information for NETSPOT™ please refer to: http://go.usa.gov/cSywA.

**About Triad Isotopes, Inc.**

Triad Isotopes Inc. is a nationwide nuclear pharmacy company headquartered in Orlando, Fla. The company's national network of more than 54 locations serves 4 million patients each year, making Triad Isotopes the nation's second-largest radiopharmaceutical provider. Triad's network of specialized facilities provide the products used by hospitals and nuclear medicine operators to help diagnose and treat patients, primarily those with cardiac and cancer concerns. For more information please visit: www.TriadIsotopes.com.

**About Nuclear Diagnostic Products, Inc.**

Nuclear Diagnostic Products has a network of three independent nuclear pharmacy locations serving the New York, New Jersey and Philadelphia areas. NDP assures the highest quality diagnostic and therapeutic radiopharmaceuticals by providing exceptional product preparation, delivery and customer service, all of which enhance our commitment to providing The Best Patient Care. To contact us, please visit www.ndprx.com.

**About Advanced Accelerator Applications**

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA's lead therapeutic product candidate, Lutathera, is a novel MNM compound that AAA is currently developing for the treatment of Neuro Endocrine Tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 20 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 440 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). AAA reported sales of €88.6 million in 2015 (+26.8% vs. 2014) and sales of €26.9 million for 1Q 2016 (+29.6% vs. 1Q15). AAA is listed on the Nasdaq Global Select Market under the ticker "AAAP". For more information please visit: www.adacap.com.

**Cautionary Statement Regarding Forward-Looking Statements**

This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our product candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates; our ability to procure adequate quantities of necessary supplies and raw materials for Lutathera and other chemical compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely and safe delivery of our products or product candidates by third parties; any problems with the manufacture, quality or performance of our products or product candidates; the rate and degree of market acceptance and the clinical utility of Lutathera and our other products or product candidates; our estimates regarding the market opportunity for Lutathera, our other product candidates and our existing products; our anticipation that we will generate higher sales as we diversify our products; our ability to implement our growth strategy including expansion in the U.S.; our ability to sustain and create additional sales, marketing and distribution capabilities; our intellectual property and licensing position; legislation or regulation in countries where we sell our products that affect product pricing, taxation, reimbursement, access or distribution channels; and general economic, political, demographic and business conditions in Europe, the U.S. and elsewhere. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

**Contacts:**

**AAA Media Relations**
Véronique Mermet
Communications Officer
info@adacap.com
Tel: +33 (0)4 50 99 30 70

**AAA Investor Relations**
Jordan Silverstein
Director of Investor Relations
jordan.silverstein@adacap.com
Tel: + 1-212-235-2394

**Media inquiries**

**FTI Consulting**
Shauna Elkin
shauna.elkin@fticonsulting.com
Tel: +1-212-850-5613

**Axess Public Relations (Italy)**
Dario Francolino
dario.francolino@axesspr.com
Tel: +39 3488818029

**Exhibit 99.4**

# PRESS RELEASE

## Cardinal Health to Prepare NETSPOT™ Doses for Advanced Accelerator Applications

*Preparing for the Launch of a Novel Kit for the Preparation of Gallium Ga 68 Dotatate for Neuroendocrine Tumor Detection*

**Saint-Genis-Pouilly, France - June 9, 2016 – Advanced Accelerator Applications S.A. (NASDAQ:AAAP)** ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), today announced that it has selected Cardinal Health, Inc. (NYSE: CAH), a healthcare services company operating the largest radiopharmaceutical network in the United States, to supply gallium 68 (Ga 68) dotatate doses prepared with a novel kit to U.S. hospitals and imaging centers.

NETSPOT™ (formerly known as Somakit-TATE) is a patented kit recently approved by the U.S. Food and Drug Administration ("FDA") for the preparation of Ga 68 dotatate for injection, for the localization of somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients using Positron Emission Tomography ("PET"). The product has received orphan drug designation from the U.S. Food and Drug Administration ("FDA").

Cardinal Health's extensive U.S. network of radiopharmaceutical manufacturing facilities will prepare and deliver NETSPOT™ patient doses to advanced medical imaging sites in key metropolitan areas where high demand is anticipated. This partnership makes Cardinal Health the second radiopharmacy network that will participate in the NETSPOT™ supply chain, after the announcement of the Zevacor Pharma partnership earlier this year.

"*We believe that NETSPOT™ has the potential to improve the accuracy of diagnosis while reducing radiation exposure for patients compared to the existing standard*," said Stefano Buono, Chief Executive Officer of AAA. "*We are pleased to have signed this non-exclusive agreement with Cardinal Health for the preparation and delivery of NETSPOT™. We believe that Cardinal Health's extensive footprint, and deep expertise in preparation of kit based products, will make it an excellent partner in creating broad availability of this innovative product. We believe the establishment of broadly available doses of Ga 68 radiopharmaceuticals will also mark an important milestone in the development of PET imaging, a development similar to the establishment of unit dose supply of Fluorine-18 labeled radiopharmaceuticals in the early 2000's*."

---


**About NETSPOT™**

NETSPOT™ is a novel patented kit developed by AAA for the preparation of gallium Ga 68 dotatate for injection, for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients using Positron Emission Tomography ("PET"). The kit has been designated as an orphan drug by the EMA and the FDA. For full prescribing information for NETSPOT™ please refer to: http://go.usa.gov/cSywA.

**About Advanced Accelerator Applications**

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA's lead therapeutic product candidate, Lutathera, is a novel MNM compound that AAA is currently developing for the treatment of Neuro Endocrine Tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 20 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 440 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). AAA reported sales of €88.6 million in 2015 (+26.8% vs. 2014) and sales of €26.9 million for 1Q 2016 (+29.6% vs. 1Q15). AAA is listed on the Nasdaq Global Select Market under the ticker "AAAP". For more information please visit: www.adacap.com.

**Cautionary Statement Regarding Forward-Looking Statements**

This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our product candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates; our ability to procure adequate quantities of necessary supplies and raw materials for Lutathera and other chemical compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely and safe delivery of our products or product candidates by third parties; any problems with the manufacture, quality or performance of our products or product candidates; the rate and degree of market acceptance and the clinical utility of Lutathera and our

other products or product candidates; our estimates regarding the market opportunity for Lutathera, our other product candidates and our existing products; our anticipation that we will generate higher sales as we diversify our products; our ability to implement our growth strategy including expansion in the U.S.; our ability to sustain and create additional sales, marketing and distribution capabilities; our intellectual property and licensing position; legislation or regulation in countries where we sell our products that affect product pricing, taxation, reimbursement, access or distribution channels; and general economic, political, demographic and business conditions in Europe, the U.S. and elsewhere. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

**Contacts:**

**AAA Media Relations**
Véronique Mermet
Communications Officer
info@adacap.com
Tel: +33 (0)4 50 99 30 70

**AAA Investor Relations**
Jordan Silverstein
Director of Investor Relations
jordan.silverstein@adacap.com
Tel: + 1-212-235-2394

**Media inquiries**

**FTI Consulting**
Shauna Elkin
shauna.elkin@fticonsulting.com
Tel: +1-212-850-5613

**Axess Public Relations (Italy)**
Dario Francolino
dario.francolino@axesspr.com
Tel: +39 3488818029

**Exhibit 99.5**

# PRESS RELEASE

## Advanced Accelerator Applications Announces Expansion of Theranostic Pipeline with NeoBOMB1

## Two Oral Presentations Featured at SNMMI Annual Meeting

**Saint-Genis-Pouilly, France – June 7, 2016 – Advanced Accelerator Applications S.A. (NASDAQ:AAAP)** ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), today announced the expansion of its pipeline of theranostic products with the addition of NeoBOMB1, a novel GRPR antagonist, and that two abstracts presenting NeoBOMB1 data have been selected for oral presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2016 Annual Meeting in San Diego, California. One of the two submissions was given the "International Best Abstract" Award.

The details of the presentations are as follows:

**Abstract #331: 68Ga/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use**
Presenter: Simone Dalm, Msc, Department of Radiology & Nuclear Medicine, Erasmus University Medical Center
Session Title: Preclinical probes for Oncology-1 - Room 29 CD
Session Date: Tuesday, June 14, 2016
Session Time: 10:00 a.m. – 10:12 a.m. ET

**Abstract #583: [68Ga]NeoBOMB1, a new potent GRPR-antagonist for PET imaging - Preclinical and first clinical evaluation in prostate cancer**
Presenter: Theodosia Maina, PhD, Director of Research, National Centre of Scientific Research "Demokritos"
Session Title: Oncology: First-in-Human Imaging Studies - Room 30 B
Session Date: Wednesday, June 15, 2016
Session Time: 8:36 a.m. – 8:48 a.m. ET

These two independent studies evaluated NeoBOMB1 in a prostate cancer model, with both diagnostic and therapeutic isotopes, including an initial clinical evaluation performed in prostate cancer patients.

NeoBOMB1 is a unique new generation antagonist bombesin analogue, which binds selectively and with high affinity to the GRP receptors expressed by several types of tumors, including prostate, breast and gastro-intestinal stromal tumors. GRP receptors are considered relevant molecular targets for both therapeutic and diagnostic purposes in those cancers. In vitro and in vivo pre-clinical models have demonstrated that NeoBOMB1 has desirable imaging properties as well as a favorable pharmacokinetic and safety profile.


"*We are broadening our pipeline with NeoBOMB1 by leveraging a formula that we have already successfully applied to develop our lead therapeutic candidate, Lutathera and diagnostic product, Somakit, which was recently approved by the US Food and Drug Administration. Our plan is to radiolabel NeoBOMB1 to develop a theranostic pair:* $^{177}$*Lu-NeoBOMB1 for treatment and a* $^{68}$*Ga-NeoBOMB1 for diagnosis. I believe NeoBOMB1 may have potential utility in PET diagnosis and as a targeted therapy in GRPR-expressing malignancies,"* said Stefano Buono, Chief Executive Officer of AAA.

NeoBOMB1 was originally developed by Marion De Jong of Erasmus University Medical Center and Theadosia Maina and Berthold Nock of Demokritos. AAA has acquired the rights to develop NeoBOMB1 and is currently planning three clinical studies in different indications including gastrointestinal stromal tumors, prostate cancer and breast cancer.

---

**About Advanced Accelerator Applications**

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA's lead therapeutic product candidate, Lutathera, is a novel MNM compound that AAA is currently developing for the treatment of Neuro Endocrine Tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 20 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 440 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). AAA reported sales of €88.6 million in 2015 (+26.8% vs. 2014) and sales of €26.92 million for 1Q 2016 (+29.6% vs. 1Q15). AAA is listed on the Nasdaq Global Select Market under the ticker "AAAP". For more information please visit: www.adacap.com.

**Cautionary Statement Regarding Forward-Looking Statements**

This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our product candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates; our ability to procure adequate quantities of

necessary supplies and raw materials for Lutathera and other chemical compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely and safe delivery of our products or product candidates by third parties; any problems with the manufacture, quality or performance of our products or product candidates; the rate and degree of market acceptance and the clinical utility of Lutathera and our other products or product candidates; our estimates regarding the market opportunity for Lutathera, our other product candidates and our existing products; our anticipation that we will generate higher sales as we diversify our products; our ability to implement our growth strategy including expansion in the U.S.; our ability to sustain and create additional sales, marketing and distribution capabilities; our intellectual property and licensing position; legislation or regulation in countries where we sell our products that affect product pricing, taxation, reimbursement, access or distribution channels; and general economic, political, demographic and business conditions in Europe, the U.S. and elsewhere. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

***Contacts***

***AAA Media Relations***
Véronique Mermet
Communications Officer
info@adacap.com
Tel: +33 (0)4 50 99 30 70

***AAA Investor Relations***
Jordan Silverstein
Director of Investor Relations
jordan.silverstein@adacap.com
Tel: + 1-212-235-2394

**Media enquiries**

**FTI Consulting**
Shauna Elkin
shauna.elkin@fticonsulting.com
Tel: +1-212-850-5613

**Axess Public Relations (Italy)**
Dario Francolino
dario.francolino@axesspr.com
Tel: +39 34888180


**Exhibit 99.6**

# PRESS RELEASE

## Advanced Accelerator Applications Expands its Presence in Germany with Strategic Acquisition of Two Production Sites

May 27, 2016, Saint-Genis-Pouilly, France – Advanced Accelerator Applications S.A. ("AAA" or "the Company") (Nasdaq: AAAP), an international specialist in Molecular Nuclear Medicine ("MNM"), announced today that AAA Germany GmbH has signed an asset purchase agreement to operate two new F-18 radiopharmaceutical production sites in South Germany. The transaction will close by June 1, 2016.

The first site, located in Erlangen, will be wholly owned and operated by AAA. The second site, located in Munich, will remain the property of the University Hospital of Munich (*Klinikum der Universität München* or KUM), with AAA responsible for production and commercialization onsite. The Munich contract includes a long-term F-18 in-house supply agreement with the KUM. Of particular value to AAA are the strong R&D activities of the KUM in radiotherapy with prostate-specific membrane antigen (PSMA) and Lutetium.

"*Advanced Accelerator Applications is very active in the European F-18 PET market with production facilities based in France, Germany, Italy, Poland, Portugal and Spain,*" noted Stefano Buono, Chief Executive Officer of AAA. "*With the addition of these two new productions sites to the one AAA is already operating in Bonn, the Company will now have three production sites in Germany and a total of 15 PET production sites in Europe. This acquisition is in line with our strategy to continue consolidating the European PET market and expand our geographical reach.*"

Gérard Ber, Chief Operating Officer of AAA added: "*Acquiring these two production sites in Germany will expand AAA's presence in Germany and enable us to cover a very significant part of the German market. With this transaction AAA will become a market leader in Germany.*"

AAA's key F-18 product is Gluscan®, its branded fluorodeoxyglucose (FDG) PET imaging agent which assists in the diagnosis of serious diseases, primarily in oncology, by assessing glucose metabolism.

---

**About Advanced Accelerator Applications**

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA's lead therapeutic product candidate, Lutathera, is a novel MNM compound that AAA is currently developing for the treatment of Neuro Endocrine Tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 18 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 440 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). In 2015 AAA reported sales of €88.6 million (+26.8% vs. 2014). AAA is listed on the Nasdaq Global Select Market under the ticker "AAAP". For more information please visit: www.adacap.com

**About Molecular Nuclear Medicine ("MNM")**

Molecular Nuclear Medicine is a medical specialty using trace amounts of active substances, called radiopharmaceuticals, to create images of organs and lesions and to treat various diseases, such as cancer. The technique works by injecting targeted radiopharmaceuticals into the patient's body that accumulate in the organs or lesions and reveal specific biochemical processes. Molecular Nuclear Diagnostics employs a variety of imaging devices and radiopharmaceuticals. PET (Positron Emission Tomography) and SPECT (Single Photon Emission Tomography) are highly sensitive imaging technologies that enable physicians to diagnose different types of cancer, cardiovascular diseases, neurological disorders and other diseases in their early stages.

**Cautionary Statement Regarding Forward-Looking Statements**

This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our product candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates; our ability to procure adequate quantities of necessary supplies and raw materials for Lutathera and other chemical compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely and safe delivery of our products or product candidates by third parties; any problems with the manufacture, quality or performance of our products or product candidates; the rate and degree of market acceptance and the clinical utility of Lutathera and our other products or product candidates; our estimates regarding the market opportunity for Lutathera, our other product candidates and our existing products; our anticipation that we will generate higher sales as we diversify our products; our ability to implement our growth strategy including expansion in the U.S.; our ability to sustain and create additional sales, marketing and distribution capabilities; our intellectual property and licensing position; legislation or regulation in countries where we sell our products that affect product pricing, taxation, reimbursement, access or distribution channels; and general economic, political, demographic and business conditions in Europe, the U.S. and elsewhere. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

***Contacts***

***AAA Media Relations***
Véronique Mermet
Communications Officer
veronique.mermet@adacap.com
Tel: +33 (0)4 50 99 30 70

***AAA Investor Relations***

Jordan Silverstein
Director of Investor Relations
jordan.silverstein@adacap.com
Tel: + 1-212-235-2394

**Media enquiries**

**FTI Consulting**
Shauna Elkin
shauna.elkin@fticonsulting.com
Tel: +1-212-850-5613

**Axess Public Relations (Italy)**
Dario Francolino
dario.francolino@axesspr.com
Tel: +39 34888180

**Exhibit 99.7**

## PRESS RELEASE

# Advanced Accelerator Applications Appoints Francois Nader, M.D., to Board of Directors

### *Healthcare Veteran Brings Expertise in Developing Innovative Therapies*

May 26, 2016, Saint-Genis-Pouilly, France – Advanced Accelerator Applications S.A. (NASDAQ:AAAP) ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), today announced that Francois Nader, M.D., MBA has joined the Company Board of Directors as an Independent Non-Executive Director.

"*Dr. Nader's guidance and perspective on global clinical development, regulatory, and commercial strategy will be of tremendous benefit as we advance our pipeline of product candidates led by Lu-DOTATATE (Lutathera ®) for the treatment of Neuro Endocrine Tumors, a significant unmet medical need,"* stated Stefano Buono, Chief Executive Officer of AAA. "*Dr. Nader's deep biopharmaceutical expertise, coupled with his experience in orphan drug product launches*, *will be extremely valuable to help guide AAA in its mission to become a leading global player in Molecular Nuclear Medicine."*

"*I am delighted to join AAA's Board of Directors. I believe that radiopharmaceuticals could represent a transformative new modality in cancer therapeutics, and I look forward to contributing to the company's growth and success,*" said Francois Nader, M.D.

Francois Nader, M.D., has over 30 years of experience in the global biopharmaceutical industry in senior operational and scientific roles. From 2008 to 2015, Dr. Nader served as the President and Chief Executive Officer of NPS Pharmaceuticals, Inc. and previously served as Chief Operating Officer in 2007, and Chief Medical and Commercial officer in 2006. During his tenure as CEO, Dr. Nader transformed NPS into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases until Shire acquired the company for $5.2B in February 2015. Dr. Nader was recognized as the EY US National Life Science Entrepreneur of the Year® in 2013.

Before joining NPS, Dr. Nader was a venture partner at Care Capital. Prior to that, he served on the North America Leadership Team of Aventis and its predecessor companies holding a number of executive positions in the U.S. and Canada, including Senior Vice President, U.S. integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon in 1981 and his Physician Executive MBA from the University of Tennessee in 2000.

Dr. Nader will be replacing Muriel de Szilbereky, who served as a Director in exemplary fashion from June 2013. The AAA Board will continue to be chaired by Claudio Costamagna, and will consist of eight Directors in total – 7 of which are independent.


---

**About Advanced Accelerator Applications**

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA's lead therapeutic product candidate, Lutathera, is a novel MNM compound that AAA is currently developing for the treatment of Neuro Endocrine Tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 18 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 440 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). In 2015 AAA reported sales of €88.6 million (+26.8% vs. 2014). AAA is listed on the Nasdaq Global Select Market under the ticker "AAAP". For more information please visit: www.adacap.com

**About Molecular Nuclear Medicine ("MNM")**

Molecular Nuclear Medicine is a medical specialty using trace amounts of active substances, called radiopharmaceuticals, to create images of organs and lesions and to treat various diseases, like cancer. The technique works by injecting targeted radiopharmaceuticals into the patient's body that accumulate in the organs or lesions and reveal specific biochemical processes. Molecular Nuclear Diagnostics employs a variety of imaging devices and radiopharmaceuticals. PET (Positron Emission Tomography) and SPECT (Single Photon Emission Tomography) are highly sensitive imaging technologies that enable physicians to diagnose different types of cancer, cardiovascular diseases, neurological disorders and other diseases in their early stages.

**Cautionary Statement Regarding Forward-Looking Statements**

This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our product candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates; our ability to procure adequate quantities of necessary supplies and raw materials for Lutathera and other chemical compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely and safe delivery of our products or product candidates by third parties; any problems with the manufacture, quality or performance of our products or product candidates; the rate and degree of market acceptance and the clinical utility of Lutathera and our other products or product candidates; our estimates regarding

the market opportunity for Lutathera, our other product candidates and our existing products; our anticipation that we will generate higher sales as we diversify our products; our ability to implement our growth strategy including expansion in the U.S.; our ability to sustain and create additional sales, marketing and distribution capabilities; our intellectual property and licensing position; legislation or regulation in countries where we sell our products that affect product pricing, taxation, reimbursement, access or distribution channels; and general economic, political, demographic and business conditions in Europe, the U.S. and elsewhere. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

***Contacts***

***AAA Media Relations***
Véronique Mermet
Communications Officer
veronique.mermet@adacap.com
Tel: +33 (0)4 50 99 30 70

***AAA Investor Relations***
Jordan Silverstein
Director of Investor Relations
jordan.silverstein@adacap.com
Tel: + 1-212-235-2394

**Media enquiries**

**FTI Consulting**
Shauna Elkin
shauna.elkin@fticonsulting.com
Tel: +1-212-850-5613

**Axess Public Relations (Italy)**
Dario Francolino
dario.francolino@axesspr.com
Tel: +39 34888180

**Exhibit 99.8**

# PRESS RELEASE

## Advanced Accelerator Applications preparing for Lutathera launch by scaling up production in Ivrea, Italy

### *Company provides update on key European production site*

May 23, 2016, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), today announced that it is scaling up its Ivrea site for Lutathera production. AAA has recently submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead Neuro Endocrine Tumor therapeutic candidate Lutathera. The EMA has recently granted Accelerated Assessment for Lutathera. The Ivrea extension is in anticipation of the NDA and MAA approvals.

The AAA Ivrea site hosts the Headquarters of AAA Italy and is located in the Bioindustry Park Silvano Fumero, between Turin and Milan. AAA started commercial operations on this site in 2008. Since then the site has almost doubled in size and increased headcount by 46 employees. The site currently covers 640sqm of laboratories and 530sqm of office space and employs 52 people.

"*The AAA Ivrea site is one of Lutathera's birth places. It is in Ivrea that Lutathera was developed from a radiochemical point of view,*" said Stefano Buono, Chief Executive Officer of AAA. "*As we ramp up for the Lutathera launch we are putting all of the pieces in place to ensure seamless production and distribution of Lutathera in Europe and in the US. The extension of the AAA Ivrea site is essential to achieve these objectives*."

"*We are proud to have such an active company in the Bioindustry Park Silvano Fumero. We have helped AAA in its journey and are happy to see that eight years after its arrival the Company is still here and growing*", said Fabrizio Conicella, Director of the Bioindustry Park Silvano Fumero.

Today the AAA Ivrea site is one of three Lutathera production sites in Europe. Lutathera is currently administered on a compassionate use and named patient basis for the treatment of NETs in ten European countries and in the US under an Expanded Access Program (EAP). All the Lutathera doses for the Lutathera NETTER-1 Phase 3 clinical trial were produced in Italy either in Ivrea or in Forlì. The Ivrea site produced all the Lutathera doses delivered to the US sites in the Phase 3 trial. The US doses for NETTER-1 represent a total of 206 doses to date. When Lutathera is approved the AAA Ivrea site will produce Lutathera for European patients and serve as a back up for our new production site in Millburn, New Jersey, for US patients when needed.

The Ivrea site should be undergoing an FDA inspection in the upcoming months for Lutathera production. It will be the second AAA site in Italy visited by the FDA. The AAA/GiPharma Saluggia site successfully completed a FDA Pre-Approval-Inspection in October 2015 prompted by the NDA submission of Somakit-TATE.


---

**About Advanced Accelerator Applications**

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA's lead therapeutic product candidate, Lutathera, is a novel MNM compound that AAA is currently developing for the treatment of Neuro Endocrine Tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 18 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 440 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). In 2015 AAA reported sales of €88.6 million (+26.8% vs. 2014). AAA is listed on the Nasdaq Global Select Market under the ticker "AAAP". For more information please visit: www.adacap.com

**Cautionary Statement Regarding Forward-Looking Statements**

This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our product candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates; our ability to procure adequate quantities of necessary supplies and raw materials for Lutathera and other chemical compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely and safe delivery of our products or product candidates by third parties; any problems with the manufacture, quality or performance of our products or product candidates; the rate and degree of market acceptance and the clinical utility of Lutathera and our other products or product candidates; our estimates regarding the market opportunity for Lutathera, our other product candidates and our existing products; our anticipation that we will generate higher sales as we diversify our products; our ability to implement our growth strategy including expansion in the U.S.; our ability to sustain and create additional sales, marketing and distribution capabilities; our intellectual property and licensing position; legislation or regulation in countries where we sell our products that affect product pricing, taxation, reimbursement, access or distribution channels; and general economic, political, demographic and business conditions in Europe, the U.S. and elsewhere. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

***Contacts***

***AAA Media Relations***
Laetitia Defaye
Head of Corporate Communications
laetitia.defaye@adacap.com
Tel: +33 (0)6 86 65 73 52

Véronique Mermet
Communications Officer
veronique.mermet@adacap.com
Tel: +33 (0)4 50 99 30 70

***AAA Investor Relations***
Jordan Silverstein
Director of Investor Relations
jordan.silverstein@adacap.com
Tel: + 1-212-235-2394

**Media enquiries**

**FTI Consulting**
Shauna Elkin
shauna.elkin@fticonsulting.com
Tel: +1-212-850-5613

**Axess Public Relations (Italy)**
Dario Francolino
dario.francolino@axesspr.com
Tel: +39 3488818029

**Exhibit 99.9**

## PRESS RELEASE

# ITEL signs agreement with Advanced Accelerator Applications to commercialize F-18 radiopharmaceuticals in Southern Italy

May 18, 2016, Ruvo di Puglia, Italy – ITEL, a leading manufacturer of medical imaging products and services, today announced that it has signed an agreement with Advanced Accelerator Applications S.A. (NASDAQ:AAAP) ("AAA") to manufacture and commercialize F-18 radiopharmaceuticals to hospitals and imaging centers in selected regions of Southern Italy.

The multiannual contract establishes that, once ITEL has completed all the qualification procedures and has been authorized by Italian Medicines Agency AIFA, the company will manufacture F-18 radiopharmaceuticals under AAA license in its production plant in Ruvo di Puglia (BA) and commercialize them across the PET centers located in select regions of Southern Italy by means of its business unit ITELPHARMA. AAA's key F-18 product is Gluscan®, its branded fluorodeoxyglucose (FDG) PET imaging agent which assists in the diagnosis of serious diseases, primarily in oncology, by assessing glucose metabolism.

*"This partnership enables us to operate not only in Apulia, but also in other nearby regions. It will allow us also to offer a more comprehensive selection of F-18 radiopharmaceuticals to nuclear medicine departments*", said Leonardo Diaferia, President of ITEL.

"*We are delighted to work with AAA, a pharmaceutical group that shares our commitment to innovation. This agreement rewards our experience in producing FDG that started in 2009 and our investments in human resources and facilities. Our plant has a double production line so that we can ensure delivery in time of radiopharmaceuticals to nuclear medicine facilities, for the benefit of partners but, above all, of patients,"* added Wilma De Feudis, Managing Director of ITEL.

"*AAA is very active in the European F-18 PET market with 13 PET production facilities based in France, Germany, Italy, Poland, Portugal and Spain*", noted Stefano Buono, Chief Executive Officer of AAA. "*This agreement will reinforce AAA's position as one of the leading companies in the F-18 PET market in Italy*."

"*This agreement completes the strategy begun with the acquisition of GE Healthcare's FDG-PET radiopharmaceutical business,"* added Enrico De Maria, Chief Executive Officer of AAA Italy. " *The partnership with Itel will enable us to produce our F-18 radiopharmaceuticals in a total of four sites in Italy. This will ensure AAA's products are better distributed across the country and offer Italian patients premium service."*

---

**About Molecular Nuclear Medicine ("MNM")**
Molecular Nuclear Medicine is a medical specialty using trace amounts of active substances, called radiopharmaceuticals, to create images of organs and lesions and to treat various diseases, like

cancer. The technique works by injecting targeted radiopharmaceuticals into the patient's body that accumulate in the organs or lesions and reveal specific biochemical processes. Molecular Nuclear Diagnostics employs a variety of imaging devices and radiopharmaceuticals. PET (Positron Emission Tomography) and SPECT (Single Photon Emission Tomography) are highly sensitive imaging technologies that enable physicians to diagnose different types of cancer, cardiovascular diseases, neurological disorders and other diseases in their early stages.

**About Advanced Accelerator Applications**
Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA's lead therapeutic product candidate, Lutathera, is a novel MNM compound that AAA is currently developing for the treatment of Neuro Endocrine Tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 18 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 440 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). In 2015 AAA reported sales of €88.6 million (+26.8% vs. 2014). AAA is listed on the Nasdaq Global Select Market under the ticker "AAAP". For more information please visit: www.adacap.com

**About Itel**
Itel Telecomunicazioni Srl (also known as Itel) is an italian company established in 1982. It has three business sectors: 1) production of radiopharmaceuticals for PET diagnostics and supply of products and services for nuclear medicine, radioprotection and microbiology; 2) design and production of integrated technologies for diagnostics, nuclear medicine and advanced radiotherapy, including "turnkey" solutions; 3) an electromagnetic compatibility test laboratory, for CE marking of electrical and electronic products. In its Research & Development laboratory, ITEL is building an industrial prototype of a special linear proton accelerator, which, by means of a patented integrated system, ERHA, will be used to treat tumors with proton therapy. For more information please visit: www.itelte.it

**Cautionary Statement Regarding Forward-Looking Statements**
This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our product candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates; our ability to procure adequate quantities of

necessary supplies and raw materials for Lutathera and other chemical compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely and safe delivery of our products or product candidates by third parties; any problems with the manufacture, quality or performance of our products or product candidates; the rate and degree of market acceptance and the clinical utility of Lutathera and our other products or product candidates; our estimates regarding the market opportunity for Lutathera, our other product candidates and our existing products; our anticipation that we will generate higher sales as we diversify our products; our ability to implement our growth strategy including expansion in the U.S.; our ability to sustain and create additional sales, marketing and distribution capabilities; our intellectual property and licensing position; legislation or regulation in countries where we sell our products that affect product pricing, taxation, reimbursement, access or distribution channels; and general economic, political, demographic and business conditions in Europe, the U.S. and elsewhere. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

***Contacts***


***Itel Media Relations***
Rosaria Malcangi
Communications Officer
r.malcangi@itelte.it
Tel: +39 080 3611033

***Itel Investor Relations***
Daniele Russo
Chief Financial Officer
d.russo@itelte.it
Tel: +39 080 3611033

***AAA Media Relations***
**Laetitia Defaye**
Head of Corporate Communications
laetitia.defaye@adacap.com
Tel: +33 (0)6 86 65 73 52

**Véronique Mermet**
Communications Officer
veronique.mermet@adacap.com
Tel: +33 (0)4 50 99 30 70

***AAA Investor Relations***
Jordan Silverstein
Director of Investor Relations
jordan.silverstein@adacap.com
Tel: + 1-212-235-2394


**Media enquiries**


**FTI Consulting**
Shauna Elkin
shauna.elkin@fticonsulting.com
Tel: +1-212-850-5613

**Axess Public Relations (Italy)**
Dario Francolino
dario.francolino@axesspr.com
Tel: +39 34888180